AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Go back to AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis| AbbVie (NYSE: ABBV) | Delayed: 256.46 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $256.46 | 52 Week High | $68.12 | |||
| Open | $256.46 | 52 Week Low | $50.71 | |||
| Day High | $256.46 | P/E | 55.63 | |||
| Day Low | $256.46 | EPS | $4.61 | |||
| Volume | 3,841 | |||||
